复方苦参注射液联合GP方案化疗治疗晚期非小细胞肺癌的临床观察

目的：观察复方苦参注射液联合GP（吉西他滨＋顺铂）方案治疗晚期非小细胞肺癌（NSCLC）的近期疗效、生活质量变化、毒副反应及疼痛缓解情况。方法：将60例晚期NSCLC患者随机分为治疗组（复方苦参注射液＋GP方案化疗）和对照组（GP方案化疗）。对照组应用吉西他滨1000mg/m2分别于第1d、8d静滴,顺铂25mg/m2,第1d、2d、3d静滴;治疗组在化疗同时加用复方苦参注射液20m L,静脉滴注,1次/d,连用2周,3周为一个周期,连续治疗两个周期。结果：治疗组临床获益率（CR＋PR＋SD）86.7%,对照组临床获益率63.3%,差异有显著性（P〈0.05）;两组治疗后Karonfsky评分提高率分别为73.3%和43.3%,差异有显著性（P〈0.05）;两组在白细胞下降、恶心、呕吐、肝功能损害方面比较有显著统计学差异性（P〈0.05）,在血小板下降、血红蛋白下降、肾功能损害方面比较无显著统计学差异性（P〉0.05）;治疗组止痛缓解率90.0%高于对照组63.3%,两组差异有显著性（P〈0.05）。结论：复方苦参注射液联合GP方案化疗治疗中晚期非小细胞肺癌可明显改善患者生活质量、减轻化疗毒副作用、缓解轻中度疼痛。

Clinical observation on treating advanced non-small cell lung cancer with the compound Kushen injection plus chemotherapy

Objective： To observe recent effects, life quality changes, adverse reaction and pain relief of the compound Kushen injection plus chemotherapy on advanced non-small cell lung cancer （NSCLC）. Methods： 60 patients were randomly divided into the treatment group （the compound Kushen injection ＋ GP chemotherapy） and the control group （GP chemotherapy）. Results： In the treatment group, clinical benefit rate （CR ＋ PR ＋ SD） was 86.7%, in the control group it was 63.3%, with significant difference （P〈0.05）; Karonfsky score increasing rate in two groups after treatment was 73.3% and 43.3% respectively, with significant difference （P〈0.05）; white blood cells decline, nausea, vomiting, liver function damage in two groups were statistically significant differences （P〈0.05）, the fall of platelet, hemoglobin, renal damage were not statistically significant difference （P〉0.05）; the pain relief rate was 90.0% in the treatment group, higher than 63.3% in the control group, with significant differences （P〈0.05）. Conclusion： The compound Kushen injection plus chemotherapy can significantly improve quality of life, reduce side effects of chemotherapy, mild-to-moderate pain relief, and show good effects on advanced non-small cell lung cancer.